|
Lantern Pharma Inc. (LTRN) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Lantern Pharma Inc. (LTRN) Bundle
Unabhängig davon, ob Sie ein Anleger oder Analyst sind, ist dieser (LTRN) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Mit realen Daten von Lantern Pharma Inc. geladen, können Sie Prognosen anpassen und die Ergebnisse sofort anzeigen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -2.4 | -5.9 | -12.3 | -14.4 | -15.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .1 | .2 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -2.4 | -5.9 | -12.4 | -14.6 | -16.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 1.2 | 19.2 | 70.7 | 55.2 | 41.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | -.2 | -.6 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .4 | .7 | .9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -2.4 | -5.9 | -12.3 | -14.4 | -16.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2.0 | -6.0 | -11.8 | -13.6 | -17.3 | .0 | .0 | .0 | .0 | .0 |
| WACC, % | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -22 | |||||||||
| Equity Value | 22 | |||||||||
| Diluted Shares Outstanding, MM | 11 | |||||||||
| Equity Value Per Share | 2.00 |
What You Will Get
- Real Lantern Pharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Lantern Pharma Inc. (LTRN).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Lantern Pharma Inc. (LTRN).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Lantern Pharma Inc. (LTRN)’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Lantern Pharma Inc. (LTRN).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Lantern Pharma Inc. (LTRN).
Key Features
- Comprehensive Financial Data: Gain access to precise historical data and future forecasts specific to Lantern Pharma Inc. (LTRN).
- Adjustable Forecast Parameters: Modify highlighted fields for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatically refresh DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to help visualize your valuation outcomes.
- Designed for All Skill Levels: An easy-to-navigate layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Lantern Pharma Inc. (LTRN) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Lantern Pharma Inc.'s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Lantern Pharma Inc. (LTRN)?
- Accurate Data: Utilize real Lantern Pharma financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple interface and guided instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Lantern Pharma Inc. (LTRN) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Lantern Pharma Inc. (LTRN).
- Consultants: Deliver professional valuation insights on Lantern Pharma Inc. (LTRN) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Lantern Pharma Inc. (LTRN) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Lantern Pharma Inc. (LTRN).
What the Template Contains
- Historical Data: Includes Lantern Pharma Inc.'s (LTRN) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Lantern Pharma Inc.'s (LTRN) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Lantern Pharma Inc.'s (LTRN) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.